Alvotech Dossier
Qualitative Analysis
Business overview
Alvotech (NASDAQ: ALVO) is a vertically integrated global biopharmaceutical company founded by Robert Wessman, dedicated solely to the development and commercial manufacture of high-quality biosimilar medicines. The company operates a state-of-the-art manufacturing facility in Reykjavik, Iceland, which allows it to control its supply chain end-to-end. Alvotech leverages a unique commercial model, partnering with leading global pharmaceutical companies such as Teva and Advanz Pharma to handle local marketing, distribution, and commercial execution across approximately 90 countries. Its portfolio features five approved and marketed biosimilars, including treatments referencing Humira (adalimumab), Stelara (ustekinumab), Simponi (golimumab), Eylea (aflibercept), and Prolia/Xgeva (denosumab), alongside a robust pipeline of candidates targeting autoimmune, ophthalmic, oncological, and respiratory conditions.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing plans to establish a second-source manufacturing site in the United States for key biosimilar products.
Expected impact: Diversifies the manufacturing footprint, reduces sole dependency on the Reykjavik facility, and mitigates regulatory and supply chain risks.
A multi-channel campaign featuring interactive webinars, 3D molecular visualizations, and regulatory primers to build trust and accelerate biosimilar adoption.
Expected impact: Reduces skepticism among payers, pharmacists, and prescribers, supporting rapid formulary placement and market share gains.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquisition of Xbrane's Swedish R&D operations at Campus Solna and the biosimilar candidate XB003 (referencing Cimzia). This expands Alvotech's development capacity and establishes a strong footprint in the Swedish life science sector.
Financial impact: Total purchase price of SEK 275 million (~$28.9 million), consisting of SEK 102.2 million in cash, assumption of SEK 152.75 million in convertible debt, and SEK 20 million in accounts payable.
Acquisition of a Swiss- and Germany-based pharmaceutical packaging and clinical supply specialist to expand downstream assembly and packaging capacity.
Financial impact: Total cash consideration of CHF 14.9 million (~$19 million). The transaction resulted in an $8 million bargain purchase gain recognized in 2025, primarily driven by the fair value uplift of acquired real estate.
Strategic Partnerships
Collaboration to co-develop, manufacture, and commercialize AVT32, a biosimilar candidate to Keytruda (pembrolizumab) for global markets.
Terms: Jointly responsible for development and manufacturing, sharing costs and responsibilities, with global commercialization rights subject to certain exceptions.
Expanded European commercial partnership to cover supply and commercialization of biosimilar candidates to Cimzia (AVT10), Ilaris (canakinumab), Kesimpta (ofatumumab), and an early-stage undisclosed candidate.
Terms: Includes development and commercial milestones totaling up to $180 million (EUR 160 million) plus revenue sharing.